The complexity of AD and its varying pathophysiological characteristics make it difficult to predict how these therapies will impact different patient subgroups, including those with different levels of tau pathology, disease stages, or varying risks of cognitive/functional decline and adverse events (AEs) [7,11-13]. This evidence concerns the gene MAPT and Alzheimer disease.